ReviewJournal of endocrinological investigation2008
Bisphosphonates in the treatment of thalassemia-associated osteoporosis.
Review in Journal of endocrinological investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Treatment for osteoporosis in people with beta-thalassaemia.The Cochrane database of systematic reviews · 2023Pooled it
- Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010Pooled it
- Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.Journal of bone and mineral metabolism · 2019Trial
- Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.The American journal of clinical nutrition · 2013Trial
- Baicalein Alleviates Iron Overload-Induced Ferroptosis and Osteogenic Blockade in Osteoblasts by Activating the Nrf2/GPX4 Pathway.BME frontiers · 2026Article
- Evaluation of Children and Adolescents with Thalassemia Major in Terms of Osteoporosis: A Single-Centre Experience.Journal of clinical medicine · 2025Article
- Trabecular bone score in the assessment of bone health in thalassemia major.Frontiers in endocrinology · 2025Article
- Should we use bisphosphonates to treat bone complications in sickle cell disease?Hematology. American Society of Hematology. Education Program · 2024Article
- Assessment of biochemical bone markers of osteoporosis in children with thalassemia major.Italian journal of pediatrics · 2022Article
- Assessment of the Nutritional Status, Bone Mineralization, and Anthropometrics of Children with Thalassemia Major.Medeniyet medical journal · 2021Article
- Association of Hydrogen Sulfide with Femoral Bone Mineral Density in Osteoporosis Patients: A Preliminary Study.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Hematological Diseases and Osteoporosis.International journal of molecular sciences · 2020Review
- Vitamin D Receptor (VDR) Gene Polymorphisms (FokI, BsmI) and their Relation to Vitamin D Status in Pediatrics βeta Thalassemia Major.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- Bone disease in adult patients with β-thalassaemia major: a case-control study.Internal and emergency medicine · 2014Article
- Predictors of bone disease in Egyptian prepubertal children with β-thalassaemia major.Archives of medical science : AMS · 2010Article
- Beta-thalassemia.Orphanet journal of rare diseases · 2010Review
- Rare causes of osteoporosis.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal DiseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia major is a common cause of skeletal morbidity, as shown by the increased fracture risk in thalassemic patients. The etiology of this bone disease is multifactorial and culminates in a state of increased bone turnover with excessive bone resorption and remodeling. Despite hormonal replacement therapy, calcium and vitamin D administration, effective iron chelation, and normalization of hemoglobin levels, patients with thalassemia major continue to lose bone mass. The increased bone turnover rate observed in thalassemic patients justifies the use of powerful anti-resorption drugs, such as bisphosphonates. To date, alendronate, pamidronate, and zoledronate seem to be effective in increasing bone mineral density and normalizing bone turnover, but more trials are necessary to evaluate their efficacy in reducing fracture risks in larger thalassemic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.